| Literature DB >> 32313182 |
Peter A Perrino1,2, Lidiya Talbot3, Rose Kirkland4,5, Amanda Hill6, Amanda R Rendall1,2, Hayley S Mountford3, Jenny Taylor4,7, Alexzandrea N Buscarello1,2, Nayana Lahiri8, Anand Saggar8, R Holly Fitch9,10, Dianne F Newbury11.
Abstract
Language development builds upon a complex network of interacting subservient systems. It therefore follows that variations in, and subclinical disruptions of, these systems may have secondary effects on emergent language. In this paper, we consider the relationship between genetic variants, hearing, auditory processing and language development. We employ whole genome sequencing in a discovery family to target association and gene x environment interaction analyses in two large population cohorts; the Avon Longitudinal Study of Parents and Children (ALSPAC) and UK10K. These investigations indicate that USH2A variants are associated with altered low-frequency sound perception which, in turn, increases the risk of developmental language disorder. We further show that Ush2a heterozygote mice have low-level hearing impairments, persistent higher-order acoustic processing deficits and altered vocalizations. These findings provide new insights into the complexity of genetic mechanisms serving language development and disorders and the relationships between developmental auditory and neural systems.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32313182 PMCID: PMC7170883 DOI: 10.1038/s42003-020-0885-5
Source DB: PubMed Journal: Commun Biol ISSN: 2399-3642
Fig. 1Discovery Family and cosegregation of USH2A variant.
Individuals affected by APD are coloured in black. Unaffected individuals are shown in white. Line through symbol indicates that individual is deceased. All descendants of individual I.1 were affected by a severe expressive language disorder. The only unaffected individuals in the family were incoming Founder members (I.2, II.2, II.3, III.4). Chromatograms show validation of USH2A variant in wider family members. The variant (position indicated by a blue highlight bar) was observed in a heterozygous form in all affected individuals.
Fig. 2Ush2a HT mice show low-frequency auditory impairments.
Relative performance on various prepulse inhibition paradigms (lower scores equal better performance). a Normal Single Tone at 15 kHz and 40 kHz displayed. b Embedded Tone 0-100 at 10.5 kHz analyzed across days using NST 15 kHz as a covariate. c Embedded Tone 0-10 at 10.5 kHz analyzed across days using NST 15 kHz as a covariate. d Pitch Discrimination at 40 kHz analyzed across days using NST 40 kHz as covariate. Data shown are mean ± SEM for each Genotype. *p < 0.05; #p < 0.15. White diamond indicates Genotype mean. All panels included 35 biologically independent animals (12 WT, 12 HT, 11 KO). Data underlying these figures are provided in Supplementary Dataset 3.
Fig. 3Ush2a HT mice produce altered ultrasonic vocalizations (USVs).
a Syllable Frequency per Genotype collapsed across syllable category. b Syllable Duration per Genotype collapsed across syllable category. c Syllable Volume per Genotype collapsed across syllable category. Data shown are mean ± SEM for each Genotype. ***p < 0.001. White diamond indicates Genotype mean. All panels included 34 biologically independent animals (12 WT, 11 HT, 11 KO). Data underlying these figures are provided in Supplementary Dataset 4.
Clinically relevant mutations observed in the UK10K dataset.
| Genome Location (hg19) | SNP ID | Ref | Alt | No. of carriers identified | QUAL score | MAF (gnomAD) | Functional effect | DNA change | Amino acid change |
|---|---|---|---|---|---|---|---|---|---|
| chr1:215956104 | rs111033264 | A | G | 1 | 24.8 | 2.889E-07 | Missense | c.10561T > C | p.Trp3521Arg |
| chr1:215963510 | rs148660051 | C | T | 4 | 247 | 0.000003829 | Missense | c.10073G > A | p.Cys3358Tyr |
| chr1:216019240 | rs397518041 | C | T | 1 | 46.4 | 0.00001627 | Stop-Gain | c.8981G> A | p.Trp2994* |
| chr1:216420436 | rs80338903 | C | – | 7 | 967 | 0.0006835 | Frameshift | c.2299delG | p.Glu767Serfs |
| chr1:216497582 | rs121912600 | C | A | 1 | 171 | 0.00004079 | Missense | c.1256G > T | p.Cys419Phe |
Genome location is given in the format chr:variant position (hg19). QUAL score refers to PHRED quality score for sequence data at given base. Ref is the allele observed in the Human Reference sequence (hg19). Alt is the alternative allele observed in the UK10K. All variants were observed in a heterozygous form. Minor Allele Frequency (MAF) is given for all samples in the gnomAD population database (https://gnomad.broadinstitute.org/). DNA change refers to the position in the coding sequence for the gene. Amino acid change refers to the position altered in the protein.
Quantitative measures of language, reading and cognition in carriers of USH2A compared to non-carriers in UK10K dataset.
| Measure | Age | Range of scores (carriers) | Mean score (carriers) | No. of non-carriers | Range of scores (non-carriers) | Mean Score (non-carriers) | SD (non-carriers) | 5th percentile | No carriers below 5th percentile |
|---|---|---|---|---|---|---|---|---|---|
| Vocabulary score | 3 years | 64–246 | 214.77 | 1601 | 0–246 | 232.42 | 24.81 | 186 | 2 of 13 |
| Plurals score | 3 years | 0–12 | 10.33 | 1594 | 1–12 | 10.32 | 2.02 | 6 | 0 of 12 |
| Past tense score | 3 years | 0–42 | 35.17 | 1584 | 0–42 | 34.23 | 9.43 | 13 | 1 of 12 |
| Word combination score | 3 years | 0–26 | 18.15 | 1593 | 0–26 | 22.79 | 4.31 | 15 | 4 of 13 |
| Reading score: WORD | 7 years | 14–45 | 27.71 | 1558 | 0–50 | 30.11 | 8.74 | 15 | 1 of 14 |
| Spelling score | 7 years | 42064 | 6.93 | 1547 | 0–15 | 8.36 | 4.27 | 2 | 0 of 14 |
| WOLD comprehension | 8 years | 41456 | 8.36 | 1557 | 2–14 | 7.76 | 1.9 | 5 | 0 of 14 |
| Nonword Repetition | 8 years | 43377 | 7.07 | 1558 | 0–12 | 7.47 | 2.46 | 3 | 0 of 14 |
| WISC—Verbal IQ | 8 years | 99–130 | 116 | 1551 | 54–155 | 112.02 | 16.73 | 86 | 0 of 14 |
| WISC—Performance IQ | 8 years | 82–132 | 102.71 | 1550 | 46–145 | 103.56 | 16.87 | 76 | 0 of 14 |
| WISC—Total IQ | 8 years | 90–132 | 111.29 | 1545 | 46–148 | 109.22 | 16.21 | 82 | 0 of 14 |
| Air conduction Right average 0.5, 1, 2, 4 kHz | 7 years | 2.5 to 12.5 | 8.08 | 1241 | −3.75 to 37.5 | 8.18 | 5.31 | 17.5 | 0 of 13 |
| Air conduction Left average 0.5, 1, 2, 4 kHz | 7 years | 0 to 16.25 | 7.79 | 1241 | −8.75 to 40 | 7.90 | 5.45 | 17.5 | 0 of 13 |
| MinMid—minimum air conduction thresholds across the left and right ears, averaged across 1, 2 and 4KHz | 7 years | −1.67 to 11.67 | 5.13 | 1263 | −8.33 to 40 | 6.48 | 5.53 | 16.67 | 0 of 13 |
| MinLow—minimum air conduction thresholds across the left and right ears at 0.5KHz | 7 years | 5 to 15 | 11.15 | 1240 | −10 to 35 | 9.96 | 5.81 | 20 | 0 of 13 |
Fifteen quantitative measures of language and hearing were compared between individuals carrying USH2A variants that have previously been reported as pathogenic and control UK10K individuals without such variants.
Discrete measures of educational support, neurodevelopmental disorders and hearing in carriers of USH2A compared to non-carriers in UK10K dataset.
| Measure | Age measured | No affected | Freq in | No. of affected non-carriers | Freq in non-carriers |
|---|---|---|---|---|---|
| Carer worried about child’s speech | 3 years | 2 of 13 | 0.15 | 120 of 1580 | 0.08 |
| Child has learning difficulties requiring special arrangements at school | 7 years | 0 of 14 | 0 | 55 of 1548 | 0.04 |
| Child has speech problems requiring special arrangements at school | 7 years | 0 of 14 | 0 | 13 of 1548 | 0.01 |
| Child has hearing problems requiring special arrangements at school | 7 years | 0 of 14 | 0 | 30 of 1548 | 0.02 |
| Child has eyesight problems requiring special arrangements at school | 7 years | 0 of 14 | 0 | 13 of 1548 | 0.01 |
| Child has physical problems requiring special arrangements at school | 7 years | 0 of 14 | 0 | 12 of 1548 | 0.01 |
| Child has reading difficulties requiring special arrangements at school | 7 years | 0 of 14 | 0 | 70 of 1548 | 0.05 |
| Child has emotional/behavioural problems requiring special arrangements at school | 7 years | 0 of 14 | 0 | 22 of 1548 | 0.01 |
| Child stutters/stumbles when speaks | 8 years | 3 of 14 | 0.21 | 119 of 1560 | 0.08 |
| DAWBA DSM-IV clinical diagnosis - Any ADHD disorder | 7 years | 0 of 14 | 0 | 20 of 1569 | 0.01 |
| Mother told child has dyslexia | 9 years | 1 of 12 | 0.08 | 71 of 1540 | 0.05 |
| Mother told child has dyspraxia | 9 years | 0 of 11 | 0 | 29 of 1513 | 0.02 |
| Mother told child has dyscalculia | 9 years | 0 of 11 | 0 | 8 of 1496 | 0.01 |
| Hearing Impairment (AC thresholds greater than 20db HL at 1,2,4 kHz) | 7 years | 0 of 13 | 0 | 114 of 1492 | 0.08 |
| OME/abnormal middle ear pressure (<−100 mm H2O) | 7 years | 5 of 14 | 0.36 | 422 of 1510 | 0.28 |
Fifteen binary measures of developmental difficulties were compared between individuals carrying USH2A variants that have previously been reported as pathogenic and control UK10K individuals without such variants.
Association analyses of variants across USH2A in relation to language and hearing outcomes.
| ALSPAC SNP-BASED analysis | Additive model | Interaction | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CHR | SNP | BP (hg19) | A1 | MinLow | MinMid | DLD | NWR | Vocab | DLD | NWR | Vocab |
| 1 | rs682319 | 216,417,675 | T | 0.0274 | 0.0706 | 0.742 | 0.804 | 0.0930 | 0.850 | 0.0914 | |
| 1 | rs11120747 | 216,438,500 | G | 0.0062 | 0.901 | 0.194 | 0.961 | 0.238 | 0.962 | 0.0454 | 0.436 |
| 1 | rs2168924 | 216,440,105 | A | 0.963 | 0.0147 | 0.463 | 0.0537 | 0.349 | 0.525 | 0.0375 | 0.393 |
| 1 | rs1159143 | 216,454,483 | T | 0.0033 | 0.115 | 0.319 | 0.720 | 0.538 | 0.789 | 0.822 | 0.0749 |
| 1 | rs10864237 | 216,466,861 | C | 0.00999 | 0.317 | 0.988 | 0.244 | 0.912 | 0.184 | 0.531 | |
| 1 | rs17651066 | 216,470,121 | C | 0.0795 | 0.0676 | 0.493 | 0.315 | 0.122 | 0.250 | 0.309 | 0.0022 |
| 1 | rs7532570 | 216,504,269 | G | 0.407 | 0.410 | 0.848 | 0.835 | 0.150 | 0.813 | 0.266 | |
| 1 | rs1606357 | 216,521,091 | T | 0.00022 | 0.0425 | 0.780 | 0.871 | 0.491 | 0.358 | 0.611 | 0.532 |
| 1 | rs17657634 | 216,552,571 | G | 0.910 | 0.153 | 0.337 | 0.0317 | 0.728 | 0.590 | 0.917 | 0.227 |
| 1 | rs4253963 | 216,592,003 | T | 0.0146 | 0.0689 | 0.734 | 0.617 | 0.160 | 0.301 | 0.688 | 0.383 |
| 1 | rs10779261 | 216,595,306 | C | 0.0340 | 0.0534 | 0.863 | 0.825 | 0.676 | 0.283 | 0.582 | 0.885 |
| 1 | rs12723493 | 216,605,071 | A | 0.0187 | 0.233 | 0.393 | 0.659 | 0.827 | 0.650 | 0.166 | 0.311 |
At the variant level, SNPs were directly associated with low-frequency hearing thresholds but not language outcomes within an additive model.
In contrast, in an interactive model, which considers interactions between variants and low-frequency hearing thresholds, association was observed with early language outcomes.
At the gene level, association to hearing measures was largely driven by common variants while association to language impairment was stronger with rare variants.
SNPs are shown for 5′ region of association only (chr1:216,438,500-216,521,091, hg19).
Bold values indicate that p-value was significant after a Bonferroni correction for multiple testing.
Pathway analyses of genes implicated in GxE interaction effects of low-frequency hearing upon vocabulary development.
| Pathway ID | Pathway description | No. Genes | P (FDR) | Matching genes |
|---|---|---|---|---|
| GO.0007155 | Cell adhesion | 21 | 0.00254 | APP,BTN3A1,CADM2,CDH18,CDH26,CLDN11,CLSTN2,CNTNAP2,COL13A1,FAT3,FOXP1,GPR56,ITGA9,ITGBL1,NUAK1,PDGFRA,PRKCA,PRKCE,PTPRK,PTPRM,SEMA5A |
| GO.0051270 | Regulation of cellular component movement | 17 | 0.00842 | ANK2,CAMK1D,DACH1,FOXP1,GPR56,MAGI2,NTRK3,PDGFRA,PLXNA4,PRKCA,PRKCE,PTPRK,PTPRM,SCN5A,SEMA5A,SYNE1,SYNE2 |
| GO.0005515 | Protein binding | 50 | 0.0382 | AGBL1,ANK2,ANLN,APP,BCL2L1,CDYL,CLDN11,CNTNAP2,CPE,DEPDC5,DLG2,DMRT3,ELMO1,ESR1,ESRRG,EXOC4,FCRL2,FOXP1,GPR56,LRRFIP1,MAGI2,MAP7,MECOM,MICALCL,NTRK3,NUAK1,PAX5,PCCA,PDGFRA,PHACTR4,PRAME,PRKCA,PRKCE,PTPRK,PTPRM,RAB11FIP4,RAD23B,RALYL,SCN5A,SEMA5A,SEPT7,SPPL2C,STXBP6,SYNE1,SYNE2,TLR1,TP73,TRIM33,USH2A,WWOX |
| GO.0071944 | Cell periphery | 58 | 4.87E-06 | ADCY9,ANK2,ANLN,APP,BNC2,BTN3A1,CADM2,CDC42BPB,CDH11,CDH18,CDH26,CLDN11,CLSTN2,CNTNAP2,COL13A1,COL23A1,CPE,DLG2,DPP10,ELMO1,EPN1,ESR1,FAT3,FCRL2,FCRL3,GPHN,GPR56,HTR1E,KCNJ1,LGR5,LRRFIP1,LYPD6B,MAGI2,MAP7,MCF2L,MDGA2,MGAM,NTRK3,PDGFRA,PLEK2,PLXNA4,PRAME,PRKCA,PRKCE,PTPRK,PTPRM,PTPRN2,RIMBP2,SCN5A,SEMA5A,SEPT7,SLC22A3,SLC7A14,STXBP6,SYNE1,SYNE2,TLR1,USH2A |
| GO.0005886 | Plasma membrane | 57 | 4.87E-06 | ADCY9,ANK2,APP,BNC2,BTN3A1,CADM2,CDC42BPB,CDH11,CDH18,CDH26,CLDN11,CLSTN2,CNTNAP2,COL13A1,COL23A1,CPE,DLG2,DPP10,ELMO1,EPN1,ESR1,FAT3,FCRL2,FCRL3,GPHN,GPR56,HTR1E,KCNJ1,LGR5,LRRFIP1,LYPD6B,MAGI2,MAP7,MCF2L,MDGA2,MGAM,NTRK3,PDGFRA,PLEK2,PLXNA4,PRAME,PRKCA,PRKCE,PTPRK,PTPRM,PTPRN2,RIMBP2,SCN5A,SEMA5A,SEPT7,SLC22A3,SLC7A14,STXBP6,SYNE1,SYNE2,TLR1,USH2A |
| GO.0016020 | Membrane | 76 | 0.00523 | ADCY9,ANK2,APP,ARHGAP15,ASTN2,ATRNL1,BCL2L1,BNC2,BTN3A1,CADM2,CDC42BPB,CDH11,CDH18,CDH26,CLDN11,CNTNAP2,COL13A1,COL23A1,CPE,CSMD1,DEPDC5,DLG2,DPP10,DPYSL2,EIF3H,ELMO1,EPN1,ESR1,FAT3,FCRL3,GPHN,GPR56,HTR1E,INPP5D,KCNJ1,KIAA1024,LGR5,LINGO2,LRRFIP1,LYPD6B,MAGI2,MAP7,MCF2L,MDGA2,MGAM,MGAT4C,MTMR7,NTRK3,PDE10A,PDGFRA,PLEK2,PLXNA4,PRAME,PRKCA,PRKCE,PTPRK,PTPRM,PTPRN2,RAB11FIP4,RIMBP2,SCN5A,SEMA5A,SEPT7,SLC22A3,SLC37A2,SLC7A14,SLC9A9,SORCS2,SPPL2C,STT3A,STXBP6,SYNE1,SYNE2,THSD7B,TLR1,USH2A |
| GO.0044459 | Plasma membrane part | 31 | 0.00523 | ADCY9,ANK2,APP,CLSTN2,CNTNAP2,COL13A1,DLG2,EPB41L3,EXOC4,FCRL2,GPHN,GPR56,HTR1E,KCNJ1,LGR5,MAP7,MGAM,NTRK3,PDGFRA,PLEK2,PTPRK,PTPRM,PTPRN2,SCN5A,SLC22A3,SLC6A6,SLC7A14,SYNE1,SYNE2,TLR1,USH2A |
| GO.0033267 | Axon part | 8 | 0.00523 | APP,CNTNAP2,DLG2,DPYSL2,EPB41L3,EPN1,PTPRN2,SEPT7 |
| GO.0044224 | Juxtaparanode region of axon | 3 | 0.00869 | CNTNAP2,DLG2,EPB41L3 |
| GO.0031252 | Cell leading edge | 10 | 0.0126 | CDC42BPB,CNTNAP2,EPB41L3,MCF2L,PHACTR4,PLEK2,PTPRK,PTPRM,SYNE1,SYNE2 |
| GO.0005911 | Cell–cell junction | 10 | 0.0126 | ANK2,APP,CDC42BPB,CLDN11,COL13A1,EPB41L3,MAGI2,PTPRK,PTPRM,SCN5A |
| GO.0031256 | Leading edge membrane | 6 | 0.0236 | CNTNAP2,EPB41L3,PLEK2,PTPRK,SYNE1,SYNE2 |
| GO.0030054 | Cell junction | 18 | 0.0236 | ANK2,APP,BCL2L1,CADM2,CDC42BPB,CLDN11,COL13A1,DLG2,EPB41L3,GPHN,MAGI2,PTPRK,PTPRM,RIMBP2,SCN5A,SYNE1,SYNE2,TP73 |
| GO.0045202 | Synapse | 13 | 0.0236 | ANK2,BCL2L1,CADM2,CLSTN2,DPYSL2,EPB41L3,EPN1,GPHN,MAGI2,PTPRN2,RIMBP2,SEPT7,SYNE1 |
| GO.0031224 | Intrinsic component of membrane | 53 | 0.0237 | ADCY9,ANK2,APP,ASTN2,ATRNL1,BCL2L1,BTN3A1,CADM2,CDH11,CDH18,CDH26,CLDN11,CLSTN2,CNTNAP2,COL13A1,COL23A1,CSMD1,DPP10,ESR1,FAT3,FCRL2,FCRL3,GPR56,HTR1E,KCNJ1,KIAA1024,LGR5,LINGO2,LYPD6B,MDGA2,MGAM,MGAT4C,NTRK3,PDGFRA,PLXNA4,PTPRK,PTPRM,PTPRN2,SCN5A,SEMA5A,SLC22A3,SLC37A2,SLC7A14,SLC9A9,SORCS2,SPPL2C,STT3A,STXBP6,SYNE1,SYNE2,THSD7B,TLR1,USH2A |
| GO.0044425 | Membrane part | 58 | 0.0257 | ADCY9,ANK2,APP,ASTN2,ATRNL1,BCL2L1,BTN3A1,CADM2,CDH11,CDH18,CDH26,CLDN11,CNTNAP2,COL13A1,COL23A1,CSMD1,DLG2,DPP10,EPB41L3,EPN1,ESR1,EXOC4,FAT3,FCRL3,GPHN,GPR56,HTR1E,KCNJ1,KIAA1024,LGR5,LINGO2,LYPD6B,MAP7,MDGA2,MGAM,MGAT4C,NTRK3,PDGFRA,PLEK2,PLXNA4,PTPRK,PTPRM,PTPRN2,SCN5A,SEMA5A,SLC22A3,SLC37A2,SLC7A14,SLC9A9,SORCS2,SPPL2C,STT3A,STXBP6,SYNE1,SYNE2,THSD7B,TLR1,USH2A |
| GO.0031258 | Lamellipodium membrane | 3 | 0.0288 | PLEK2,SYNE1,SYNE2 |
| GO.0098805 | Whole membrane | 24 | 0.039 | ANK2,APP,BCL2L1,CLSTN2,CNTNAP2,CPE,DEPDC5,DLG2,EPB41L3,EPN1,GPHN,ITGA9,MAP7,MGAM,PLEK2,PTPRN2,RAB11FIP4,SCN5A,SLC7A14,SLC9A9,SYNE1,SYNE2,TLR1,USH2A |
| GO.0016021 | Integral component of membrane | 51 | 0.039 | ADCY9,ANK2,APP,ASTN2,ATRNL1,BCL2L1,BTN3A1,CADM2,CDH11,CDH18,CDH26,CLDN11,CLSTN2,CNTNAP2,COL13A1,COL23A1,CSMD1,DPP10,ESR1,FAT3,FCRL2,FCRL3,GPR56,HTR1E,KCNJ1,KIAA1024,LGR5,LINGO2,MGAM,MGAT4C,NTRK3,PDGFRA,PLXNA4,PTPRK,PTPRM,PTPRN2,SCN5A,SEMA5A,SLC22A3,SLC37A2,SLC7A14,SLC9A9,SORCS2,SPPL2C,STT3A,STXBP6,SYNE1,SYNE2,THSD7B,TLR1,USH2A |
| GO.0042995 | Cell projection | 22 | 0.039 | ANK2,CADM2,CLSTN2,CNTNAP2,DPYSL2,EPB41L3,EPN1,EXOC4,GPR56,MAGI2,MCF2L,PDGFRA,PHACTR4,PLEK2,PRKCA,PTPRK,PTPRM,PTPRN2,SYNE1,SYNE2,TSPEAR,USH2A |
| GO.0030424 | Axon | 9 | 0.0452 | CADM2,CNTNAP2,DLG2,DPYSL2,EPB41L3,EPN1,PTPRK,PTPRN2,SEPT7 |
All GO terms with FDR P < 0.05 are listed.